Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity / Bozzetti, C; Musolino, A; Camisa, R; Bisagni, G; Flora, M; Bassano, C; Martella, E; Lagrasta, Costanza Anna Maria; Nizzoli, R; Personeni, N; Leonardi, F; Cocconi, G; ARDIZZONI A., RELATED ARTICLES; Links,. - In: AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS. - ISSN 0277-3732. - 29(2):(2006), pp. 171-177.
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
MUSOLINO A;LAGRASTA, Costanza Anna Maria;
2006-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
